From the Division of Rheumatology, Department of Pediatrics, Division of Immunology, Department of Internal Medicine, Department of Medical Genetics, Department of Medical Biochemistry, Hacettepe University Faculty of Medicine; Hacettepe University Center for Fanconi Anemia and Other Inherited Bone Marrow Failure Syndromes, Ankara, Turkey.
S. Özen, MD, Division of Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine; Y. Bilginer, MD, Division of Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine; E.D. Batu, MD, Division of Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine; E.Z. Taşkıran, PhD, Department of Medical Genetics, Hacettepe University Faculty of Medicine; H.A. Özkara, MD, PhD, Department of Medical Biochemistry, Hacettepe University Faculty of Medicine; Ş. Ünal, MD, Hacettepe University Center for Fanconi Anemia and Other Inherited Bone Marrow Failure Syndromes; N. Güleray, MD, Department of Medical Genetics, Hacettepe University Faculty of Medicine; A. Erden, MD, Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine; Ö. Karadağ, MD, Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine; F. Gümrük, MD, Hacettepe University Center for Fanconi Anemia and Other Inherited Bone Marrow Failure Syndromes; M. Çetin, MD, Hacettepe University Center for Fanconi Anemia and Other Inherited Bone Marrow Failure Syndromes (retired); H.E. Sönmez, MD, Division of Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine; D.Ç. Ayvaz, MD, Division of Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine; I. Tezcan, MD, Division of Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine. E.D. Batu and E.Z. Taşkıran contributed equally to this study.
J Rheumatol. 2020 Jan;47(1):117-125. doi: 10.3899/jrheum.181384. Epub 2019 May 1.
Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disorder associated with mutations. We aimed to investigate the characteristics and ADA2 enzyme activities of patients with DADA2 compared to non-DADA2 patients.
This is a descriptive study of 24 patients with DADA2 who were admitted to the Adult and Pediatric Rheumatology, Pediatric Haematology, and Pediatric Immunology Departments of Hacettepe University. All exons were screened by Sanger sequencing. Serum ADA2 enzyme activity was measured by modified spectrophotometric method.
Twenty-four patients with DADA2 were included: 14 with polyarteritis nodosa (PAN)-like phenotype (Group 1); 9 with Diamond-Blackfan anemia (DBA)-like features, and 1 with immunodeficiency (Group 2). Fourteen PAN-like DADA2 patients did not have the typical thrombocytosis seen in classic PAN. Inflammatory attacks were evident only in Group 1 patients. Serum ADA2 activity was low in all patients with DADA2 except one, who was tested after hematopoietic stem cell transplantation. There was no significant difference in ADA2 activities between PAN-like and DBA-like patients. In DADA2 patients with one mutation, serum ADA2 activities were as low as those of patients with homozygote DADA2. ADA2 activities were normal in non-DADA2 patients. mutations were affecting the dimerization domain in Group 1 patients and the catalytic domain in Group 2 patients.
We suggest assessing ADA2 activity along with genetic analysis because there are patients with one mutation and absent enzyme activity. Our data suggest a possible genotype-phenotype correlation in which dimerization domain mutations are associated with PAN-like phenotype, and catalytic domain mutations are associated with hematological manifestations.
腺苷脱氨酶 2(ADA2)缺乏症是一种常染色体隐性自身炎症性疾病,与 突变有关。我们旨在研究与非-DADA2 患者相比,DADA2 患者的特征和 ADA2 酶活性。
这是一项对 24 名 ADA2 患者的描述性研究,这些患者被收入哈塞泰佩大学成人和儿科风湿病科、儿科血液科和儿科免疫学。通过 Sanger 测序筛选所有外显子。通过改良分光光度法测量血清 ADA2 酶活性。
共纳入 24 名 DADA2 患者:14 名具有结节性多动脉炎(PAN)样表型(第 1 组);9 名具有 Diamond-Blackfan 贫血(DBA)样特征,1 名具有免疫缺陷(第 2 组)。14 名 PAN 样 DADA2 患者没有经典 PAN 中所见的典型血小板增多症。炎症发作仅见于第 1 组患者。除 1 名接受造血干细胞移植后检测的患者外,所有 DADA2 患者的血清 ADA2 活性均较低。PAN 样和 DBA 样患者的 ADA2 活性无显著差异。在具有一个 突变的 DADA2 患者中,血清 ADA2 活性与纯合子 DADA2 患者的活性一样低。非-DADA2 患者的 ADA2 活性正常。 突变影响第 1 组患者的二聚化结构域和第 2 组患者的催化结构域。
我们建议评估 ADA2 活性和基因分析,因为存在具有一个 突变和无酶活性的患者。我们的数据表明,可能存在基因型-表型相关性,其中二聚化结构域突变与 PAN 样表型相关,而催化结构域突变与血液学表现相关。